PFA Pension Forsikringsaktieselskab Buys Shares of 265,498 Stryker Corporation $SYK

Key Points

• PFA Pension Forsikringsaktieselskab bought a new stake of 265,498 Stryker shares in Q4 valued at about $94.02 million, representing roughly 0.07% of the company.
• Stryker missed Q1 estimates—adjusted EPS $2.60 vs. $2.98 expected and revenue $6.02B vs. $6.34B—after a cyber incident disrupted production and pressured margins, but management maintained FY‑2026 guidance of $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth.
• Insider activity: Director Ronda E. Stryker sold 250,000 shares for about $90.73 million (a 9.23% reduction in her position), while several analysts have cut price targets, weighing on near‑term upside expectations.

PFA Pension Forsikringsaktieselskab bought a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 265,498 shares of the medical technology company's stock, valued at approximately $94,018,000. PFA Pension Forsikringsaktieselskab owned approximately 0.07% of Stryker as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. United Financial Planning Group LLC bought a new stake in shares of Stryker during the third quarter worth $27,000. Strive Asset Management LLC bought a new stake in shares of Stryker during the third quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Stryker during the third quarter worth $34,000. Copia Wealth Management increased its position in shares of Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company's stock worth $40,000 after acquiring an additional 69 shares in the last quarter. Finally, WPG Advisers LLC increased its position in shares of Stryker by 156.8% during the third quarter. WPG Advisers LLC now owns 113 shares of the medical technology company's stock worth $42,000 after acquiring an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker maintained its FY‑2026 outlook — $14.90–$15.10 adjusted EPS and 8%–9.5% organic sales growth — signaling management’s confidence in recovery from the cyber incident. Article Title
• Positive Sentiment: Operational cash flow and net income showed notable improvement year-over-year (operating cash flow jumped and net income rose), which supports longer‑term cash generation and capital investment. Article Title
• Neutral Sentiment: Stryker will present at the Bank of America Global Healthcare Conference on May 13 — an opportunity for management to address the cyber recovery and investor questions, but not an immediate catalyst for results. Article Title
• Negative Sentiment: Q1 results missed consensus: adjusted EPS of $2.60 vs. ~ $2.98 expected and revenue of $6.02B vs. ~$6.34B. Management cited a cyber incident that disrupted production, pressured margins and slowed growth — the primary driver of today’s selling pressure. Article Title
• Negative Sentiment: Several Wall Street firms cut Stryker price targets this morning (JPMorgan to $400, Wells Fargo to $418, Needham/BTIG lowered targets) — ratings largely remain buy/overweight but lower targets reduce near‑term upside expectations and add selling pressure. Article Title

Stryker Stock Performance

Shares of SYK stock opened at $295.43 on Friday. The stock has a market cap of $113.15 billion, a P/E ratio of 35.17, a P/E/G ratio of 1.84 and a beta of 0.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The company has a fifty day moving average price of $345.67 and a two-hundred day moving average price of $356.95. Stryker Corporation has a one year low of $294.55 and a one year high of $404.87.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts' consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.74%. The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.91 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Stryker's dividend payout ratio (DPR) is currently 41.90%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on SYK shares. Truist Financial lowered their price objective on shares of Stryker from $395.00 to $380.00 and set a "hold" rating for the company in a research report on Wednesday, April 15th. Raymond James Financial raised shares of Stryker from a "market perform" rating to an "outperform" rating and set a $418.00 price objective for the company in a research report on Tuesday, January 6th. Citigroup lowered their price objective on shares of Stryker from $420.00 to $385.00 and set a "buy" rating for the company in a research report on Tuesday, April 7th. The Goldman Sachs Group restated a "neutral" rating and set a $361.00 target price on shares of Stryker in a report on Friday. Finally, JPMorgan Chase & Co. reduced their target price on shares of Stryker from $445.00 to $400.00 and set an "overweight" rating for the company in a report on Friday. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $401.43.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm's stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.60% of the company's stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.